DOI: 10.1055/s-00000005

Aktuelle Rheumatologie

References

Nash P, Kirkham B, Okada M. et al.
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.

Lancet 2017;
389: 2317-2327

Download Bibliographical Data

Access:
Access: